|
LPCN | Lipocine Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.25 |
| Leverage | 12.01% |
| Market Cap | $ 56.9m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -5.5m |
| Margin | -160.77% |
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceuticals for the treatment of metabolic and endocrine disorders. The company is headquartered in Salt Lake City, Utah.